Longitudinal expression profiling identifies a poor risk subset of patients with ABC-type diffuse large B-cell lymphoma

Despite the effectiveness of immuno-chemotherapy, 40% of patients with diffuse large B-cell lymphoma (DLBCL) experience relapse or refractory disease. Longitudinal studies have previously focused on the mutational landscape of relapse but fell short of providing a consistent relapse-specific genetic...

Descripción completa

Detalles Bibliográficos
Autores principales: Bewicke-Copley, Findlay, Korfi, Koorosh, Araf, Shamzah, Hodkinson, Brendan, Kumar, Emil, Cummin, Thomas, Ashton-Key, Margaret, Barrans, Sharon, van Hoppe, Suzan, Burton, Cathy, Elshiekh, Mohamed, Rule, Simon, Crosbie, Nicola, Clear, Andrew, Calaminici, Maria, Runge, Hendrik, Hills, Robert K., Scott, David W., Rimsza, Lisa M., Menon, Geetha, Sha, Chulin, Davies, John R., Nagano, Ai, Davies, Andrew, Painter, Daniel, Smith, Alexandra, Gribben, John, Naresh, Kikkeri N., Westhead, David R., Okosun, Jessica, Steele, Andrew, Hodson, Daniel J., Balasubramanian, Sriram, Johnson, Peter, Wang, Jun, Fitzgibbon, Jude
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2022
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986713/
https://www.ncbi.nlm.nih.gov/pubmed/35947123
http://dx.doi.org/10.1182/bloodadvances.2022007536

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9986713/
https://www.ncbi.nlm.nih.gov/pubmed/35947123
http://dx.doi.org/10.1182/bloodadvances.2022007536

Ejemplares similares